NCT00006343View on ClinicalTrials.gov

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Leukemia
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

cytarabine

DRUG

imatinib mesylate

Trial Locations (1)

07936

Novartis Pharmaceuticals Corporation, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Novartis

INDUSTRY